179624-53-4

Upstream product

• 160648-19-1 (E)-3-[6-(ethoxycarbonyl)pyridin-3-yl]acrylic acid 
• 179626-19-8 2-amino-N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-N-methylacetamide 
• 28507-46-2 4-chloro-8-hydroxy-2-methylquinoline 
• 179626-16-5 N-[2,4-dichloro-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)phenyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-methylacetamide 
• 179626-56-3 2-methyl-4-(4-morpholinyl)-8-quinolinol 
• 167837-49-2 2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 167837-48-1 N-(2,4-dichloro-3-(hydroxymethyl)phenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 

Downstream Products

• 179624-69-2 5-[(1E)-3-({2-[2,4-dichloro(methyl)-3-({[2-methyl-4-(4-morpholinyl)-8-quinolinyl]oxy}methyl)anilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-2-pyridinecarboxylic acid 

Relevant academic research and scientific papers

A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore to Determine Species Difference and Agonist/Antagonist Profile

Introduction of various aliphatic amino groups at the 4-position of the quinoline moiety of our nonpeptide bradykinin (BK) B2 receptor antagonists afforded highly potent ligands for human B2 receptor with various affinities for guine

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk